Gilead’s Next Chapter

Daniel O’Day - January 13, 2020

Today, at the J.P. Morgan Healthcare Conference in San Francisco, I will talk to the investment community about Gilead’s next chapter. I am looking forward to sharing the work we are doing to build on Gilead’s remarkable legacy. It is a legacy that includes two of the most extraordinary advances in healthcare of the past decade: curing HCV and helping to transform HIV into a chronic disease. This is the foundation for our next chapter as we look to apply the same high bar to other diseases. 

At J.P. Morgan, I will highlight the three key pillars of our future: 

  • Our Strong Base 
    Within the last decade, we launched 15 antiviral therapies and became the leading innovator in HIV. Today eight out of ten people living with HIV who are on therapy in the U.S. are taking a Gilead medication. We will sustain this leadership by continuing to meet the needs of patients. Our teams are pursuing innovation across the continuum of HIV care – prevention, treatment and a potential cure.

  • Our Pipeline Opportunities
    Beyond our core business, our current pipeline includes potential therapies for inflammatory diseases, such as Rheumatoid Arthritis and cancer. We have 14 late-stage studies underway – four of which have Breakthrough Therapy Designation. We are working to strengthen and diversify this existing pipeline while keeping a focus on our core areas of expertise in antivirals and immunomodulation – harnessing the body’s immune system to fight disease. 

  • Our Strategy to Supplement Innovation and Drive Growth 
    Over the next decade, we are aiming to introduce 10 new transformative therapies. To help us achieve that ambition, we will expand our access to external innovation. We have already been very active in business development, with 32 strategic partnerships and investment transactions over the past two years. We will continue to pursue a broad range of transactions with a clear focus on our core scientific areas. 

With these three pillars, our exceptional talent and our inherent strengths, we all feel very confident that Gilead has an exciting future ahead. Underpinning all of this is the incredible dedication and passion that I’ve witnessed since joining the company ten months ago. Gilead’s commitment goes beyond scientific advances. There is a strong focus on disease awareness, care and prevention in partnership with local communities. 

Our 11,000+ employees want to build a better, healthier world for every person to live in. As we enter the next decade, we are committed to making that happen. 

Our next chapter is underway, and I’m honored to be a part of it.